TIGIT-Targeted Immunotherapeutics
TIGIT-Targeted Immunotherapeutics – Target Pipeline List 02/2020
Target: TIGIT; T-cell immunoreceptor with immunoglobulin and ITIM domains; VSIG9; VSTM3; WUCAM
This Target Pipeline List provides an overview of TIGT-targeted immuno-oncology therapeutics in development as monotherapy or in combination with other checkpoint inhibitors.
T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), an immune checkpoint receptor, can suppress T-cell activation and promote T-cell exhaustion. Inhibition of TIGIT may increase cytotoxic T-cell proliferation and function. TIGIT is an immune checkpoint receptor on cytotoxic, memory, and Tregs, as well as NK cells. In cancer, tumor cells exploit the inhibitory TIGIT pathway to avoid immune-mediated destruction. Based on preclinical studies, inhibition of TIGIT alone or in combination with other checkpoint inhibitors increases the proliferation and function of cytotoxic T cells.
La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.
The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.
Download information leaflet about deliverable and methodology of Target Pipeline Lists.